Insider trades
Ian Mortimer, CEO of Xenon Pharmaceuticals XENE, has filed 0 purchases and 25 sales on the open market. Over the past 12 months that comes to a net sale of $21.3M. The latest trade was on 03/13.
Ian Mortimer
President & CEO
- Company
- Xenon Pharmaceuticals XENE
- First filing
- 23/03/14
- Trades
- 64 trades
- Buys / sales
- 0 / 25
- 12-month net buying
- −$21.3M
- Last trade
- 03/13
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
| Open-market sale10b5-1 plan | 03/13 | 03/13 | 7,308 sh | $55.23 | $403,620.84 | −26.8% | |
XENE | Open-market sale10b5-1 plan | 03/09–03/10 | 03/11 | 281,269 sh10 trades | $60.32avg. | $16,966,522.09 | −95.0% |
XENE | Open-market sale10b5-1 plan | 01/02 | 01/02 | 40,000 sh2 trades | $44.43avg. | $1,777,092.86 | −87.0% |
XENE | Open-market sale10b5-1 plan | 25/12/05–25/12/08 | 25/12/09 | 25,205 sh3 trades | $45.33avg. | $1,142,513.25 | −80.8% |
| Open-market sale10b5-1 plan | 25/11/28 | 25/12/03 | 97 sh | $45.01 | $4,365.97 | −0.3% | |
| Open-market sale10b5-1 plan | 25/10/01 | 25/10/01 | 25,000 sh | $40.16 | $1,004,000 | −44.4% | |
XENE | Open-market sale10b5-1 plan | 25/01/23–25/01/27 | 25/01/27 | 55,000 sh4 trades | $40.25avg. | $2,213,996.75 | −63.7% |
XENE | Open-market sale | 23/05/24 | 23/05/26 | 31,655 sh3 trades | $41.41avg. | $1,310,931.02 | −50.3% |